ZA200300641B - Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder. - Google Patents
Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder. Download PDFInfo
- Publication number
- ZA200300641B ZA200300641B ZA200300641A ZA200300641A ZA200300641B ZA 200300641 B ZA200300641 B ZA 200300641B ZA 200300641 A ZA200300641 A ZA 200300641A ZA 200300641 A ZA200300641 A ZA 200300641A ZA 200300641 B ZA200300641 B ZA 200300641B
- Authority
- ZA
- South Africa
- Prior art keywords
- group
- compound
- alkyl group
- mania
- medicament
- Prior art date
Links
- 206010026749 Mania Diseases 0.000 title claims description 23
- 208000020925 Bipolar disease Diseases 0.000 title claims description 15
- 238000011282 treatment Methods 0.000 title description 9
- 150000001408 amides Chemical class 0.000 title description 7
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical class CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- -1 carboxybenzyl Chemical group 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 125000006177 alkyl benzyl group Chemical group 0.000 claims description 3
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 3
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000002946 cyanobenzyl group Chemical group 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000006277 halobenzyl group Chemical group 0.000 claims description 3
- 125000005059 halophenyl group Chemical group 0.000 claims description 3
- 125000006289 hydroxybenzyl group Chemical group 0.000 claims description 3
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000006502 nitrobenzyl group Chemical group 0.000 claims description 3
- 125000006501 nitrophenyl group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical class [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 5
- 208000013403 hyperactivity Diseases 0.000 description 5
- 229960003965 antiepileptics Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 229960000604 valproic acid Drugs 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 125000004802 cyanophenyl group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22010200P | 2000-07-21 | 2000-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200300641B true ZA200300641B (en) | 2004-01-26 |
Family
ID=22822065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200300641A ZA200300641B (en) | 2000-07-21 | 2003-01-23 | Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6555585B2 (zh) |
| EP (1) | EP1303289A4 (zh) |
| JP (1) | JP2004520263A (zh) |
| KR (1) | KR100843703B1 (zh) |
| CN (1) | CN1251758C (zh) |
| AU (1) | AU2001280699A1 (zh) |
| CA (1) | CA2416821A1 (zh) |
| CZ (1) | CZ2004266A3 (zh) |
| HU (1) | HUP0600526A2 (zh) |
| IL (1) | IL153942A0 (zh) |
| MX (1) | MXPA03000547A (zh) |
| NO (1) | NO20030295L (zh) |
| NZ (1) | NZ523917A (zh) |
| PL (1) | PL365588A1 (zh) |
| WO (1) | WO2002007677A2 (zh) |
| ZA (1) | ZA200300641B (zh) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100843703B1 (ko) * | 2000-07-21 | 2008-07-04 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 | 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도 |
| AU2003289782A1 (en) * | 2002-12-16 | 2004-07-09 | The University Of British Columbia | Valproic acid analogues and pharmaceutical compositions thereof |
| US20040176463A1 (en) * | 2003-02-05 | 2004-09-09 | Daniella Licht | Immediate release formulation of n-(2-propylpentanoyl)glycinamide |
| WO2004071421A2 (en) * | 2003-02-05 | 2004-08-26 | Teva Pharmaceutical Industries Ltd. | Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds |
| IL157751A0 (en) * | 2003-02-28 | 2004-03-28 | Yissum Res Dev Co | New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them |
| IL156203A0 (en) * | 2003-05-29 | 2003-12-23 | Yissum Res Dev Co | Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders |
| EP1491188A1 (en) * | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
| US20060004098A1 (en) | 2003-07-28 | 2006-01-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compounds useful for treating neurological disorders |
| EP1713486A4 (en) * | 2003-12-02 | 2009-04-29 | Sheldon Leslie James | COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY |
| WO2006012603A2 (en) * | 2004-07-22 | 2006-02-02 | Nps Pharmaceuticals, Inc. | Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases |
| WO2007028030A2 (en) * | 2005-09-02 | 2007-03-08 | Picobella, Llc | Oncogenic regulatory rnas for diagnostics and therapeutics |
| US7459280B2 (en) * | 2006-02-27 | 2008-12-02 | Picobella, Llc | Methods for diagnosing and treating kidney cancer |
| US20080267977A1 (en) * | 2007-04-26 | 2008-10-30 | Friedrich-Alexander University Of Erlangen-Nuremberg | Combined immunological agent and sensitizing agent for the treatment of cancer |
| CA2936158C (en) | 2014-02-05 | 2023-06-13 | Yeda Research And Development Co. Ltd. | Use of mir-135 or precursor thereof for the treatment and diagnosis of a bipolar disease |
| KR102635938B1 (ko) * | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| IL282188A (en) | 2021-04-08 | 2022-11-01 | Yeda Res & Dev | Combined use of ketamine and bretigabine for the treatment of psychiatric disorders |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU988188A3 (ru) | 1973-12-14 | 1983-01-07 | Эсакмадьяросаги Ведьимювек (Инопредприятие) | Способ получени N,N-дизамещенных амидов карбоновых кислот |
| DE3050800C2 (zh) | 1979-03-22 | 1989-06-22 | Continental Pharma Inc., Bruessel/Bruxelles, Be | |
| US4301176A (en) * | 1980-08-18 | 1981-11-17 | Warner-Lambert Company | Method of administering calcium valproate |
| FR2489319A1 (fr) | 1980-08-27 | 1982-03-05 | Clin Midy | Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant |
| BE885303A (fr) | 1980-09-19 | 1981-03-19 | Continental Pharma | Glycinamides |
| LU83729A1 (fr) * | 1981-11-04 | 1983-09-01 | Galephar | Sels d'acide valproique,leur preparation et leur utilisation |
| DK373383A (da) | 1982-08-20 | 1984-02-21 | Midit | Fremgangsmaade til fremstilling af omega-aminosyrederivater |
| US4913906B1 (en) | 1985-02-28 | 2000-06-06 | Yissum Res Dev Co | Controlled release dosage form of valproic acid |
| IT1190133B (it) | 1986-06-19 | 1988-02-10 | Chiesi Farma Spa | Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| DE3785667T2 (de) | 1986-09-17 | 1994-07-21 | Clintec Nutrition Co | Zusatznahrung bzw. therapie für personen mit risiko oder in behandlung für arteriosklerotische vaskuläre, kardiovaskuläre und/oder thrombotische erkrankungen. |
| US5169642A (en) * | 1988-06-24 | 1992-12-08 | Abbott Laboratories | Sustained-release drug dosage units |
| US6287598B1 (en) * | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
| US5585358A (en) | 1993-07-06 | 1996-12-17 | Yissum Research Development Corporation Of The Hebrew University Of Jerusalem | Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents |
| CN1494907A (zh) | 1996-03-25 | 2004-05-12 | 治疗疼痛的药物组合物 | |
| IL121268A0 (en) | 1997-07-09 | 1998-01-04 | Dpharm Ltd | Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders |
| KR20010071572A (ko) | 1998-06-22 | 2001-07-28 | 아메리칸 바이오지네틱 사이언스, 인코포레이티스 | 발프로산 유사체를 편두통 및 기분 장애의 치료 및 예방에사용하는 용도 |
| KR100843703B1 (ko) * | 2000-07-21 | 2008-07-04 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 | 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도 |
-
2001
- 2001-07-20 KR KR1020037000586A patent/KR100843703B1/ko not_active IP Right Cessation
- 2001-07-20 WO PCT/US2001/023116 patent/WO2002007677A2/en active IP Right Grant
- 2001-07-20 HU HU0600526A patent/HUP0600526A2/hu unknown
- 2001-07-20 EP EP01959110A patent/EP1303289A4/en not_active Withdrawn
- 2001-07-20 IL IL15394201A patent/IL153942A0/xx not_active IP Right Cessation
- 2001-07-20 PL PL01365588A patent/PL365588A1/xx not_active Application Discontinuation
- 2001-07-20 JP JP2002513415A patent/JP2004520263A/ja active Pending
- 2001-07-20 US US09/910,543 patent/US6555585B2/en not_active Expired - Fee Related
- 2001-07-20 CA CA002416821A patent/CA2416821A1/en not_active Abandoned
- 2001-07-20 AU AU2001280699A patent/AU2001280699A1/en not_active Abandoned
- 2001-07-20 CN CNB018139663A patent/CN1251758C/zh not_active Expired - Fee Related
- 2001-07-20 MX MXPA03000547A patent/MXPA03000547A/es active IP Right Grant
- 2001-07-20 NZ NZ523917A patent/NZ523917A/en unknown
- 2001-07-20 CZ CZ2004266A patent/CZ2004266A3/cs unknown
-
2003
- 2003-01-20 NO NO20030295A patent/NO20030295L/no not_active Application Discontinuation
- 2003-01-23 ZA ZA200300641A patent/ZA200300641B/en unknown
- 2003-04-28 US US10/425,375 patent/US20030212142A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20030295D0 (no) | 2003-01-20 |
| NO20030295L (no) | 2003-01-20 |
| WO2002007677A2 (en) | 2002-01-31 |
| MXPA03000547A (es) | 2004-04-05 |
| WO2002007677A3 (en) | 2002-05-30 |
| KR100843703B1 (ko) | 2008-07-04 |
| EP1303289A4 (en) | 2009-08-05 |
| US20030212142A1 (en) | 2003-11-13 |
| CA2416821A1 (en) | 2002-01-31 |
| US20020103237A1 (en) | 2002-08-01 |
| NZ523917A (en) | 2004-11-26 |
| IL153942A0 (en) | 2003-07-31 |
| JP2004520263A (ja) | 2004-07-08 |
| CN1446097A (zh) | 2003-10-01 |
| KR20030036610A (ko) | 2003-05-09 |
| CN1251758C (zh) | 2006-04-19 |
| HUP0600526A2 (en) | 2006-11-28 |
| CZ2004266A3 (cs) | 2005-02-16 |
| AU2001280699A1 (en) | 2002-02-05 |
| US6555585B2 (en) | 2003-04-29 |
| EP1303289A2 (en) | 2003-04-23 |
| PL365588A1 (en) | 2005-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200300641B (en) | Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder. | |
| JP4154237B2 (ja) | 異痛症および他の種々のタイプの慢性疼痛または幻肢痛を治療するための化合物のペプチドクラスの新規使用 | |
| DE60127459T2 (de) | Verwendung von aminosäurehaltigen Antikonvulsiva zur Behandlung von Schmerz | |
| US20020052418A1 (en) | Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders | |
| EA018607B1 (ru) | Применение лакозамида для лечения рефрактерного эпилептического статуса | |
| CA2303815A1 (en) | N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain | |
| WO2000067755A1 (en) | Cyclic amidines useful as nmda nr2b antagonists | |
| JPH05132430A (ja) | 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法 | |
| US6960687B2 (en) | Derivatives and pharmaceutical compositions of n-hydroxyalkyl tetramethylcyclopropane-carboxamide, having anti-epiletic, neurological, and CNS activity, and method for their preparation | |
| AU2007200901B2 (en) | Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder | |
| JP4362457B2 (ja) | 神経因性疼痛治療剤 | |
| EP1896031B1 (en) | Thiazolopyrimidines for use in therapy | |
| AU2001288308B2 (en) | Valproic acid derivatives for the treatment of pain | |
| AU2001288308A1 (en) | Valproic acid derivatives for the treatment of pain |